[Skip to Navigation]
July 1971

AMA Drug Evaluations: A Praiseworthy Venture

Author Affiliations

Durham, NC

Arch Intern Med. 1971;128(1):147-148. doi:10.1001/archinte.1971.00310190151020

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The past decade has witnessed a rising groundswell of concern regarding many of the circumstances which surround the evaluation, marketing, and prescription of drugs within the United States. This concern has arisen from increasingly varied sources and, in turn, it has led to a barrage of frequently legitimate criticism toward the current practices, policies, and attitudes of governmental regulatory agencies, the pharmaceutical industry, hospitals, medical schools, physicians, etc. Under-manned regulatory agencies have been said to be too autocratic, inflexible, and generally unprepared to deal squarely and simultaneously with the special needs of industry, research, and the consumer; the pharmaceutical industry has been accused of gross commercialism, misleading and superabundant advertising, and inadequate evaluation of drug safety and efficacy; hospitals and medical schools have been brought to task for the provision of too little instruction in clinical pharmacology for students and house officers; physicians themselves have been said to be too

First Page Preview View Large
First page PDF preview
First page PDF preview
Add or change institution